CA
PRTK

Cliff Asness’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Cliff Asness’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-26,115
Closed -$178K – 2362
2021
Q2 		$178K Sell
26,115
-6,511
-20% -$52.6K ﹤0.01% 2151
2021
Q1 		$230K Hold
32,626
– – ﹤0.01% 2076
2020
Q4 		$204K Buy
32,626
+1,630
+5% +$9.59K ﹤0.01% 2087
2020
Q3 		$168K Buy
30,996
+18,719
+152% +$92.7K ﹤0.01% 2087
2020
Q2 		$64K Buy
+12,277
New +$54.5K ﹤0.01% 2078
2018
Q2 		– Sell
-12,789
Closed -$166K – 2401
2018
Q1 		$166K Sell
12,789
-5,642
-31% -$84K ﹤0.01% 2170
2017
Q4 		$330K Hold
18,431
– – ﹤0.01% 2042
2017
Q3 		$463K Buy
+18,431
New +$429K ﹤0.01% 1969
2014
Q3 		– Sell
-17,443
Closed -$417K – 2611
2014
Q2 		$417K Hold
17,443
– – ﹤0.01% 2074
2014
Q1 		$645K Hold
17,443
– – ﹤0.01% 1920
2013
Q4 		$703K Buy
17,443
+14,717
+540% +$625K ﹤0.01% 1892
2013
Q3 		$104K Buy
+2,726
New +$97.6K ﹤0.01% 2424

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cliff Asness's PRTK Position: Q3 2021 in Review

Cliff Asness sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 26,115 shares — an estimated $178K sold.

Cliff Asness first reported a position in PRTK in Q3 2013 and held it in 12 quarters. The position peaked at $703K in Q4 2013. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Cliff Asness reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Cliff Asness sold 26,115 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $178K.
  • Cliff Asness first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2013 and held it in 12 quarters.
  • Cliff Asness's Paratek Pharmaceuticals, Inc. position peaked at $703K in Q4 2013.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on AQR Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.